Senti Biosciences, Inc. (NASDAQ:SNTI) Short Interest Update

Senti Biosciences, Inc. (NASDAQ:SNTI) was the target of a significant drop in short interest in the month of March. As of March 15th, there was short interest totalling 39,600 shares, a drop of 43.8% from the February 28th total of 70,400 shares. Based on an average trading volume of 62,300 shares, the days-to-cover ratio is currently 0.6 days. Approximately 0.4% of the shares of the stock are short sold.

Senti Biosciences Price Performance

NASDAQ:SNTI opened at $3.33 on Friday. The stock has a market cap of $16.08 million, a PE ratio of -0.21 and a beta of 2.52. Senti Biosciences has a fifty-two week low of $1.52 and a fifty-two week high of $16.94. The stock’s 50-day moving average is $3.90 and its two-hundred day moving average is $3.47.

Senti Biosciences (NASDAQ:SNTI) last announced its quarterly earnings data on Thursday, March 20th. The company reported ($0.67) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.13) by $2.46. The firm had revenue of $5.86 million for the quarter, compared to analysts’ expectations of $2.80 million. On average, equities research analysts anticipate that Senti Biosciences will post -14.54 earnings per share for the current year.

Analyst Ratings Changes

Separately, Chardan Capital reaffirmed a “buy” rating and set a $10.00 target price on shares of Senti Biosciences in a research note on Monday, December 2nd.

Institutional Trading of Senti Biosciences

An institutional investor recently bought a new position in Senti Biosciences stock. Renaissance Technologies LLC bought a new position in shares of Senti Biosciences, Inc. (NASDAQ:SNTI) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 51,600 shares of the company’s stock, valued at approximately $181,000. Renaissance Technologies LLC owned about 1.07% of Senti Biosciences at the end of the most recent reporting period. Institutional investors own 25.73% of the company’s stock.

Senti Biosciences Company Profile

Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.